

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



INSIDE INFORMATION

This announcement is made by the board (the “**Board**”) of directors (the “**Directors**”) of Clover Biopharmaceuticals, Ltd. (the “**Company**” or “**Clover**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

References are made to (i) the voluntary announcement issued by the Company dated September 15, 2022 in relation to the amendment to the Advance Purchase Agreement entered into by and between Clover HK and Gavi (the “**Amendment Agreement**”); and (ii) the inside information announcement issued by the Company dated March 24, 2025 in relation to a notice of termination of the Advance Purchase Agreement and a letter of claim for repayment of the US\$224 million Advance Payment Amounts, in each case issued by Gavi to Clover HK (collectively, the “**Announcements**”). Unless indicated otherwise, capitalized terms used in this announcement shall have the same meanings as those defined in the Announcements.

The Board wishes to inform the shareholders of the Company and potential investors that, on June 6, 2025, Clover HK received an arbitration request filed by Gavi against Clover HK, claiming the repayment of the Advance Payment Amounts (the “**Claim**”). Consistent with the Announcements, the Company believes the Claim is without merit based on the terms of the Advance Purchase Agreement and will defend itself vigorously.

The Group continues with its objectives to advancing the development of its proprietary RSV vaccine candidate SCB-1019 utilized in an RSV re-vaccination setting and as part of a respiratory combination vaccine.

Shareholders of the Company and potential investors are advised to exercise with caution when dealing in the shares of the Company.

By order of the Board
Clover Biopharmaceuticals, Ltd.
Dr. Peng LIANG
Chairman of the Board

Shanghai, PRC, June 9, 2025

As at the date of this announcement, the Board comprises Dr. Peng LIANG and Mr. Joshua G LIANG as executive directors, Dr. Xiaodong WANG, Dr. Donna Marie AMBROSINO and Dr. Ralf Leo CLEMENS as non-executive directors and Dr. Xiaobin WU, Mr. Xiang LIAO, Mr. Jeffrey FARROW and Mr. Thomas LEGGETT as independent non-executive directors.